BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2015

View Archived Issues

New RNAi drug using extrahepatic delivery platform shows promise for metastatic ccRCC

Read More

Targeting retinal VEGR receptors, a promising strategy for retinal angiogenesis disorders

Read More

Malaria protein targets toxins to cancer cells

Read More

Grifols opens Bioscience Division global operations facility in Ireland

Read More

ABT-126 shows antidyskinetic effects in animal models

Read More

CDRD and viDA Therapeutics partner to discover treatments for DLE

Read More

Roche reports third quarter 2015 progress

Read More

Vasculotide, a potential treatment of Alzheimer's disease

Read More

TRPV1 and TRPA1 activation reduces muscular cramps

Read More

Acalabrutinib receives U.S. orphan designation for Waldenstrom macroglobulinemia

Read More

Auris Medical and King's College London to collaborate on small-molecule tinnitus therapy

Read More

FDA grants deflazacort orphan drug designation for pediatric juvenile idiopathic arthritis

Read More

Ares Trading patents novel INF-beta protein analogues

Read More

Amakem presents LIMK-1 and/or LIMK-2 inhibitors

Read More

Merck & Co. discloses TrKA inhibitors

Read More

Emory University develops AEP inhibitors

Read More

Arrowhead describes targeted RNAi therapeutics for HBV, renal cell carcinoma, cardiovascular disease

Read More

XOMA starts phase II trial of XOMA-358 in patients with congenital hyperinsulinism

Read More

Aeglea BioTherapeutics doses first patient in phase I study of AEB-1102 for solid tumors

Read More

Mast Therapeutics begins phase II study of vepoloxamer for chronic heart failure

Read More

RedHill Biopharma reports topline results from phase I trial of Yeliva

Read More

CHMP recommends extension of approval of rilpivirine to adolescents with HIV infection

Read More

Phase I trial of ISIS-GSK4-LRx triggers milestone payment to Isis Pharmaceuticals

Read More

Pembrolizumab superior to docetaxel in overall survival of patients with advanced NSCLC

Read More

MMP-12 inhibitors described in recent Bayer Schering Pharma patents

Read More

Bristol-Myers Squibb reports HIV maturation inhibitors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing